The estimated Net Worth of George M Jr Milne is at least $15.6 Million dollars as of 18 May 2023. George Milne owns over 8,733 units of Charles River Laboratories International stock worth over $15,241,921 and over the last 21 years he sold CRL stock worth over $0. In addition, he makes $344,856 as Lead Independent Director at Charles River Laboratories International.
George has made over 22 trades of the Charles River Laboratories International stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 8,733 units of CRL stock worth $1,690,621 on 18 May 2023.
The largest trade he's ever made was buying 20,000 units of Charles River Laboratories International stock on 2 March 2023 worth over $178,200. On average, George trades about 2,088 units every 79 days since 2003. As of 18 May 2023 he still owns at least 78,733 units of Charles River Laboratories International stock.
You can see the complete history of George Milne stock trades at the bottom of the page.
Dr. George M. Milne Jr. Ph.D. is Lead Independent Director of Charles River Laboratories International Inc. He is a Venture partner of Radius Ventures LLC since 2003. Dr. Milne retired from Pfizer Inc. in 2002 after a 32-year career encompassing a broad array of management responsibilities, including as Executive Vice President, Pfizer Global Research and Development; President, Worldwide Strategic and Operations Management; President of Central Research with global responsibility for Pfizer's Human and Veterinary Medicine Research and Development; Senior Vice President of Pfizer Inc.; and a member of the Pfizer Management Council. Dr. Milne serves on the board of Aurinia Pharmaceuticals and several private companies and charitable organizations. In the past five years, he has served on the boards of Mettler-Toledo International, Inc. and Athersys, Inc. Dr. Milne has been a director since 2002. With his strong scientific background (including a Ph.D. in Organic Chemistry), his long tenure at Pfizer Inc., his work as a venture partner with Radius Ventures and through his service on multiple life science boards, Dr. Milne has a deep understanding of R&D processes and the services, tools, and technologies used in the life sciences industry, and supplies particular insights into industry drivers as well as the concerns and perspectives of the consumers of our products and services. In addition, he has had exposure to strategic and operational issues relevant to board leadership through his prior roles at Pfizer and on other public and private company boards. Dr. Milne also brings a unique industry perspective from his biomedical venture capital activities through Radius Ventures.
As the Lead Independent Director of Charles River Laboratories International, the total compensation of George Milne at Charles River Laboratories International is $344,856. There are 10 executives at Charles River Laboratories International getting paid more, with James Foster having the highest compensation of $17,722,100.
George Milne is 76, he's been the Lead Independent Director of Charles River Laboratories International since 2013. There are no older and 20 younger executives at Charles River Laboratories International.
George's mailing address filed with the SEC is #140, 14315 ? 118 AVENUE, , EDMONTON, A0, T5L 4S6.
Over the last 22 years, insiders at Charles River Laboratories International have traded over $220,588,205 worth of Charles River Laboratories International stock and bought 18,392 units worth $3,841,397 . The most active insiders traders include James C Foster, Richard F Wallman, and David P Johst. On average, Charles River Laboratories International executives and independent directors trade stock every 14 days with the average trade being worth of $2,223,188. The most recent stock trade was executed by Joseph W La Plume on 8 August 2024, trading 1,780 units of CRL stock currently worth $354,861.
charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro
Charles River Laboratories International executives and other stock owners filed with the SEC include: